e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Insight into mechanisms of respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients
H. Fischer, B. Fischer, S. Tzotzos, H. Pietschmann, R. Lucas (Vienna, Austria; Augusta, United States Of America)
Source:
Annual Congress 2011 - Insight into mechanisms of respiratory infections
Session:
Insight into mechanisms of respiratory infections
Session type:
Poster Discussion
Number:
3503
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Fischer, B. Fischer, S. Tzotzos, H. Pietschmann, R. Lucas (Vienna, Austria; Augusta, United States Of America). Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients. Eur Respir J 2011; 38: Suppl. 55, 3503
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Impacts of inhaled corticosteroids on antiviral and antibacterial immunity in the lung
Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection
Year: 2019
Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008
Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018
Year: 2019
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Morphological evidence of anti-inflammatory effect of interferon-α at pulmonary TB patients
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008
An influence of small doses of corticosteroids on immune defense in active pulmonary tuberculosis in humans
Source: Annual Congress 2009 - Clinical immunology of tuberculosis
Year: 2009
Macrolide effects on the prevention of COPD exacerbations
Source: Eur Respir J 2012; 40: 485-494
Year: 2012
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
Inflammatory phenotypes of asthma determine effect of inhaled corticosteroids on anti-viral immunity
Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Year: 2020
Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013
Antituberculous activity of fiurenizid in vitro and in patients with destructive pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 724s
Year: 2004
Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis
Source: Eur Respir J 2012; 40: 271-273
Year: 2012
Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020
Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012
Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 197s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept